Published in Drug Saf on January 01, 2008
Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A (2012) 1.97
Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg (2011) 1.68
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ (2015) 1.52
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther (2016) 1.40
Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging (2010) 1.14
Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today? N Z Med J (2013) 1.09
Integrative chemical-biological read-across approach for chemical hazard classification. Chem Res Toxicol (2013) 1.01
New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag (2010) 0.84
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. PLoS One (2012) 0.84
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics (2014) 0.82
Developing potent human uric acid transporter 1 (hURAT1) inhibitors. J Med Chem (2011) 0.81
New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis (2010) 0.81
Activation of peripheral KCNQ channels relieves gout pain. Pain (2015) 0.80
Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol (2014) 0.79
Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents. PLoS One (2013) 0.79
Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis (2012) 0.79
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evid (2010) 0.79
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep (2016) 0.78
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol (2016) 0.76
Efficacy and Safety of Chinese Medicinal Herbs for the Treatment of Hyperuricemia: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med (2016) 0.76
Measuring interference of drug-like molecules with the respiratory chain: toward the early identification of mitochondrial uncouplers in lead finding. Assay Drug Dev Technol (2013) 0.76
Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice. Acta Pharmacol Sin (2013) 0.76
The epidemiology and treatment of gout. Open Access Rheumatol (2011) 0.75
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis (2016) 0.75
Refractory gout attack. Case Rep Med (2012) 0.75
Taking the stress out of managing gout. Can Fam Physician (2009) 0.75
Gout: optimizing treatment to achieve a disease cure. Ther Adv Chronic Dis (2016) 0.75
Enhancement of pharmacological effects of uricosuric agents by concomitant treatment with pyrazinamide in rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Lesinurad: what the nephrologist should know. Clin Kidney J (2017) 0.75
Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. BMC Complement Altern Med (2017) 0.75
CareTrack: assessing the appropriateness of health care delivery in Australia. Med J Aust (2012) 4.46
Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet (2007) 3.58
Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med (2010) 2.81
Clinical pharmacokinetics of metformin. Clin Pharmacokinet (2011) 2.59
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors. Med J Aust (2002) 2.37
Evaluating medicines: let's use all the evidence. Med J Aust (2007) 2.32
Pethidine in emergency departments: promoting evidence-based prescribing. Med J Aust (2005) 2.18
Does computerized provider order entry reduce prescribing errors for hospital inpatients? A systematic review. J Am Med Inform Assoc (2009) 2.09
Death and morbidity from supratherapeutic dosing of colchicine. Med J Aust (2011) 2.02
Emerging roles for phospholipase A2 enzymes in cancer. Biochimie (2010) 1.86
Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust (2005) 1.75
Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible? Med J Aust (2004) 1.65
Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ (2013) 1.60
The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology (2013) 1.56
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 1.40
Utility of urine drug screening: a clinical audit. Emerg Med Australas (2007) 1.39
Adverse event reporting in clinical trials: room for improvement. Med J Aust (2003) 1.29
Towards the delivery of appropriate health care in Australia. Med J Aust (2012) 1.27
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet (2007) 1.23
Effects of two commercial electronic prescribing systems on prescribing error rates in hospital in-patients: a before and after study. PLoS Med (2012) 1.22
Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf (2013) 1.22
Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res (2004) 1.21
Errors and electronic prescribing: a controlled laboratory study to examine task complexity and interruption effects. J Am Med Inform Assoc (2010) 1.16
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther (2006) 1.16
Antibacterial actions of secreted phospholipases A2. Review. Biochim Biophys Acta (2007) 1.15
Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett (2005) 1.14
Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 1.11
Failure to utilize functions of an electronic prescribing system and the subsequent generation of 'technically preventable' computerized alerts. J Am Med Inform Assoc (2012) 1.11
Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol (2002) 1.08
Hypouricemic effects of prednisone and allopurinol: an uneven playing field? Can J Cardiol (2013) 1.07
The influence of computerized decision support on prescribing during ward-rounds: are the decision-makers targeted? J Am Med Inform Assoc (2011) 1.05
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Aust New Zealand Health Policy (2007) 0.99
Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet (2013) 0.99
PACE--the first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskelet Disord (2010) 0.98
Long-term patterns of online evidence retrieval use in general practice: a 12-month study. J Med Internet Res (2008) 0.98
The safety of electronic prescribing: manifestations, mechanisms, and rates of system-related errors associated with two commercial systems in hospitals. J Am Med Inform Assoc (2013) 0.96
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet (2008) 0.96
Tolerability of paracetamol. Drug Saf (2005) 0.95
Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust (2011) 0.95
Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol (2013) 0.95
Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. Biochem Pharmacol (2009) 0.93
Prioritising drug and therapeutics committee (DTC) decisions: a national survey. Pharm World Sci (2006) 0.93
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology (2010) 0.91
PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials (2013) 0.90
Learning from hackers: open-source clinical trials. Sci Transl Med (2012) 0.90
CareTrack Australia: assessing the appropriateness of adult healthcare: protocol for a retrospective medical record review. BMJ Open (2012) 0.89
Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Br J Clin Pharmacol (2003) 0.88
Hyperuricemia, cardiovascular disease, and the metabolic syndrome. J Rheumatol (2009) 0.88
Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk. Age Ageing (2010) 0.87
The role of computerized decision support in reducing errors in selecting medicines for prescription: narrative review. Drug Saf (2011) 0.87
Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy. Am J Med Sci (2008) 0.86
The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust (2013) 0.85
The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol (2012) 0.85
Recent developments in targeting access to high cost medicines in Australia. Aust New Zealand Health Policy (2005) 0.84
Accessing health outcome data on high-cost medicines in Australia. Med J Aust (2006) 0.84
A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism. J Biol Chem (2010) 0.83
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol (2011) 0.83
Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol (2010) 0.83
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Des (2002) 0.82
Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf (2007) 0.82
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. Antivir Ther (2009) 0.82
Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. BMC Health Serv Res (2012) 0.82
"It looks after me": how older patients make decisions about analgesics for osteoarthritis. Arthritis Care Res (Hoboken) (2011) 0.81
Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust (2007) 0.81
Republished research: non-steroidal anti-inflammatory drugs (NSAIDs). Br J Sports Med (2013) 0.80
Can predictors of response to NSAIDs be identified in patients with acute low back pain? Clin J Pain (2009) 0.80
Diabetes education: the experiences of young adults with type 1 diabetes. Diabetes Ther (2014) 0.79
A proposal for identifying the low renal uric acid clearance phenotype. Arthritis Res Ther (2010) 0.79
Protocol for the Quick Clinical study: a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice. BMC Med Inform Decis Mak (2006) 0.79